Literature DB >> 220548

Nephrogenous cyclic AMP as a parathyroid function test.

A E Broadus.   

Abstract

In man, the total amount of cyclic AMP (cAMP) excreted in urine is derived from (a) the filtered load of the nucleotide and (b) cAMP formed de novo in the kidney (nephrogenous cAMP, NcAMP). NcAMP is the only pool of the nucleotide easily quantified in vivo and appears to provide a specific index of the effects of circulating, active parathyroid hormone. Elevated values for NcAMP (4.64 +/- 1.95 nmol/100 ml GF, mean +/- SD) were found in 90% or more of 115 patients with primary hyperparathyroidism, and low values (0.31 +/- 0.16 nmol/100 ml GF, mean +/- SD) were noted in 41 individuals with absent or suppressed parathyroid function. When properly expressed (as a function of glomerular filtration rate), results for the total cAMP excretion provided similar findings. The measurement of NcAMP provides a sensitive index of parathyroid function over the entire range of parathyroid activity and has proven to be an optimal method for assessing parathyroid suppressibility in response to intravenous or oral calcium administration. These techniques, the 'calcium injection test' and the 'oral calcium tolerance test', are useful in evaluation a number of subtle disorders of calcium metabolism.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 220548     DOI: 10.1159/000181623

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  9 in total

1.  Hormonal regulation of potassium shifts during graded exhausting exercise.

Authors:  F J Laso; J M González-Buitrago; C Martín Ruiz; S de Castro
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1991

2.  Humoral hypercalcemia complicating adenosquamous carcinoma of the proximal colon.

Authors:  C H Berkelhammer; A L Baker; G E Block; D G Bostwick; F Michelassi
Journal:  Dig Dis Sci       Date:  1989-01       Impact factor: 3.199

3.  The effect of intravenous magnesium sulphate on parathyroid function in primary hyperparathyroidism.

Authors:  I R Gough; G A Balderson; H M Lloyd; J Galligan; D Willgoss; B G Fryar
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

4.  The hypercalcemic rat Leydig cell tumor--a model of the humoral hypercalcemia of malignancy.

Authors:  D A Sica; R R Martodam; J Aronow; G R Mundy
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

5.  Functional asymmetry in phosphate transport and its regulation in opossum kidney cells: parathyroid hormone inhibition.

Authors:  S J Reshkin; J Forgo; H Murer
Journal:  Pflugers Arch       Date:  1990-08       Impact factor: 3.657

6.  Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation.

Authors:  Joshua N VanHouten; Pamela Dann; Andrew F Stewart; Christine J Watson; Michael Pollak; Andrew C Karaplis; John J Wysolmerski
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

7.  Vitamin D status after total gastrectomy.

Authors:  K Kozawa; M Imawari; H Shimazu; O Kobori; T Osuga; Y Morioka
Journal:  Dig Dis Sci       Date:  1984-05       Impact factor: 3.199

8.  Phosphate and the development of nephrocalcinosis in rats fed diets containing alpha protein.

Authors:  R K Zalups; P Haase; D J Philbrick
Journal:  Am J Pathol       Date:  1983-10       Impact factor: 4.307

9.  Oral calcium tolerance test and serum calcitonin in calcium stone formers.

Authors:  K Kohri; K Kataoka; M Iguchi; S Yachiku; T Kurita
Journal:  Urol Res       Date:  1983
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.